Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-13
DOI
10.1111/1346-8138.16128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies
- (2020) M. Augustin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Guselkumab: Short‐term effectiveness and safety in real clinical practice
- (2020) Lourdes Rodriguez Fernandez‐Freire et al. Dermatologic Therapy
- A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
- (2020) J. Seneschal et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study
- (2020) A.‐C. Fougerousse et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Real‐life experience of guselkumab in patients with psoriasis
- (2020) Igor Snast et al. Dermatologic Therapy
- Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study
- (2020) F. Benhadou et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
- (2020) Neuza da Silva et al. PLoS One
- Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
- (2020) Marco Galluzzo et al. Journal of Clinical Medicine
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
- (2019) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Complete Skin Clearance and PASI response rates in clinical practice‐ Predictors, Health Related Quality of Life improvements and implications for treatment goals
- (2019) J. M. Norlin et al. BRITISH JOURNAL OF DERMATOLOGY
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A safety evaluation of guselkumab for the treatment of psoriasis
- (2018) M. Galluzzo et al. Expert Opinion On Drug Safety
- Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
- (2018) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial
- (2017) April Armstrong et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”
- (2016) Anna Langenbruch et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- The German National Program on Psoriasis Health Care 2005–2015: results and experiences
- (2016) M. Augustin et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary
- (2015) Susan D. Mathias et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC
- (2015) A. Nast et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- German psoriasis registry PsoBest: objectives, methodology and baseline data
- (2014) Matthias Augustin et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- US FDA patient-reported outcome guidance: great expectations and unintended consequences
- (2013) Sheri Fehnel et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Quality of life and sexual health in patients with genital psoriasis
- (2011) K.A.P. Meeuwis et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
- (2010) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- European S3-Guidelines on the systemic treatment of psoriasis vulgaris
- (2009) D Pathirana et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis
- (2008) Luigi Naldi et al. DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More